Cisplatin/Vinblastine

顺铂/长春碱

Report date: 2024/07/10 11:08:12

Base Information

Drug NameCisplatin/Vinblastine
Drug Alias Name长春碱/顺铂Vinblastine/Cisplatincisplatin + vinblastine顺铂+长春碱长春碱+顺铂 +[10] 
ClassificationSmall molecules
Mechanisms of ActionAlkylating agentsTubulin polymerisation inhibitorsDNA cross linking agents +[5] 
TargetsTubulinDNA
Therapy Area/IndicationsLung NeoplasmsHead and Neck NeoplasmsPancreatic Neoplasms +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesGermany +[6] 
CombinationsYes Vinblastine SulfateCisplatin
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesIntensity Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesSwiss Cancer InstituteIntensity Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsLung NeoplasmsHead and Neck NeoplasmsPancreatic Neoplasms +[11] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A